Michael Harrington - Elanco Animal Independent Director

ELAN Stock  USD 16.17  0.28  1.76%   

Director

Mr. Michael J. Harrington is an Independent Director of the Company. Mr. Harrington has served as a director on Elancos board since September 2018. Mr. Harrington has served as the Senior Vice President and General Counsel for Lilly since January 2013. Prior to 2013, Mr. Harrington served in various legal roles for Lilly, including Vice President and Deputy General Counsel of Global Pharmaceutical Operations from 2010 to 2012 and Vice President and General Counsel, Corporationrationrate from 2004 to 2010. Mr. Harringtons experience described above, including his knowledge of Elanco and the animal health industry and his business and management experience, provides him with the qualifications and skills to serve as a director on Elancos board. since 2018.
Age 58
Tenure 6 years
Address 2500 Innovation Way, Greenfield, IN, United States, 46140
Phone877 352 6261
Webhttps://www.elanco.com

Michael Harrington Latest Insider Activity

Tracking and analyzing the buying and selling activities of Michael Harrington against Elanco Animal stock is an integral part of due diligence when investing in Elanco Animal. Michael Harrington insider activity provides valuable insight into whether Elanco Animal is net buyers or sellers over its current business cycle. Note, Elanco Animal insiders must abide by specific rules, including filing SEC forms every time they buy or sell Elanco Animal'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.

Elanco Animal Management Efficiency

The company has return on total asset (ROA) of 0.0139 % which means that it generated a profit of $0.0139 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.1822) %, meaning that it created substantial loss on money invested by shareholders. Elanco Animal's management efficiency ratios could be used to measure how well Elanco Animal manages its routine affairs as well as how well it operates its assets and liabilities. As of the 28th of March 2024, Return On Capital Employed is likely to grow to 0.03, though Return On Assets are likely to grow to (0.08). As of the 28th of March 2024, Asset Turnover is likely to grow to 0.33, while Total Assets are likely to drop about 13.6 B.
The company currently holds 5.77 B in liabilities with Debt to Equity (D/E) ratio of 0.87, which is about average as compared to similar companies. Elanco Animal Health has a current ratio of 1.92, which is within standard range for the sector. Debt can assist Elanco Animal until it has trouble settling it off, either with new capital or with free cash flow. So, Elanco Animal's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Elanco Animal Health sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Elanco to invest in growth at high rates of return. When we think about Elanco Animal's use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing other executives

DIRECTOR Age

Willard DereSeres Therapeutics
64
Werner CautreelsSeres Therapeutics
N/A
Carina Olofsson23Andme Holding Co
42
Ettore Artioli23Andme Holding Co
N/A
Tadataka YamadaAgilent Technologies
74
Staffan Gavel23Andme Holding Co
67
Bruce KovnerMadrigal Pharmaceuticals
69
Stephen ConnellyEquillium
42
Dow WilsonAgilent Technologies
61
Paul ClarkAgilent Technologies
72
Lorence KimSeres Therapeutics
43
Kurt GravesSeres Therapeutics
50
David BerrySeres Therapeutics
37
Salvatore Falco23Andme Holding Co
46
Anthony TjanEquillium
N/A
Martha DemskiEquillium
65
Sue RatajAgilent Technologies
63
Americo Romano23Andme Holding Co
58
Hans BishopAgilent Technologies
56
Dennis AusielloSeres Therapeutics
72
Heidi FieldsAgilent Technologies
60
Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. Elanco Animal Health Incorporated was founded in 1954 and is headquartered in Greenfield, Indiana. Elanco Animal operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on New York Stock Exchange. It employs 9000 people. Elanco Animal Health (ELAN) is traded on New York Stock Exchange in USA. It is located in 2500 Innovation Way, Greenfield, IN, United States, 46140 and employs 9,300 people. Elanco Animal is listed under Pharmaceuticals category by Fama And French industry classification.

Management Performance

Elanco Animal Health Leadership Team

Elected by the shareholders, the Elanco Animal's board of directors comprises two types of representatives: Elanco Animal inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Elanco. The board's role is to monitor Elanco Animal's management team and ensure that shareholders' interests are well served. Elanco Animal's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Elanco Animal's outside directors are responsible for providing unbiased perspectives on the board's policies.
Jose Simas, Executive Vice President U.S. Farm Animal Business
Joshua Smiley, Independent Director
Chris Keeley, Senior Officer
Carl McMillian, Independent Director
Katy Grissom, Head Relations
Ellen Brabander, Executive Vice President - Innovation and Regulatory Affairs
Sarena Lin, Executive Vice President, Global Marketing, Corporate Strategy and Transformation
Paul Herendeen, Independent Director
Racquel Mason, Executive Vice President and Chief Marketing Officer, Elanco Animal Health
Rajeev Modi, Executive Vice President - U.S. Pet Health and Global Digital Transformation
Jeffrey Simmons, President, Chief Executive Officer, Director
Denise ScotsKnight, Independent Director
David Kinard, Executive Vice President, Human Resources, Corporate Affairs and Administration
David Urbanek, Executive Vice President - Manufacturing, Quality
Aaron Schacht, Executive Vice President, Innovation, Regulatory and Business Development
R Hoover, Independent Chairman of the Board
Larbi Lier, Senior Asia
Kirk McDonald, Independent Director
James Meer, Senior Vice President, Chief Accounting Officer
Art Garcia, Independent Director
Shiv ONeill, General President
Joyce Lee, Executive Vice President and President U.S. Pet Health and Commercial Operations
David Hoover, Chairman of the Board
Kapila Anand, Independent Director
Michael Harrington, Independent Director
Todd Young, Chief Financial Officer, Executive Vice President
David Ricks, Independent Director
Marcela Kirberger, Executive Vice President General Counsel, Company Secretary
Scott Ferguson, Independent Director
Shawn McKee, Sr Animal
Deborah Kochevar, Independent Director
Lawrence Kurzius, Independent Director
Ramiro Cabral, Executive Vice President - Elanco International and Global Customer Value
Aarti Shah, Independent Director
Dirk Ehle, Executive Vice President and President Elanco Europe
William Doyle, Independent Director
John Bilbrey, Independent Director
MichaelBryant Hicks, Executive Vice President General Counsel, Secretary

Elanco Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Elanco Animal a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Elanco Animal Investors Sentiment

The influence of Elanco Animal's investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in Elanco. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock market does not have solid backing from leading economists and market statisticians.
Investor biases related to Elanco Animal's public news can be used to forecast risks associated with an investment in Elanco. The trend in average sentiment can be used to explain how an investor holding Elanco can time the market purely based on public headlines and social activities around Elanco Animal Health. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Elanco Animal's market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Elanco Animal's and other traded tickers. The bigger the bubble, the more accurate is the estimated score. Higher bars for a given day show more participation in the average Elanco Animal's news discussions. The higher the estimated score, the more favorable is the investor's outlook on Elanco Animal.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Elanco Animal in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Elanco Animal's short interest history, or implied volatility extrapolated from Elanco Animal options trading.

Pair Trading with Elanco Animal

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Elanco Animal position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Elanco Animal will appreciate offsetting losses from the drop in the long position's value.

Moving together with Elanco Stock

  0.83EQ Equillium Financial Report 9th of May 2024 PairCorr

Moving against Elanco Stock

  0.7VALN Valneva SE ADR Financial Report 2nd of May 2024 PairCorr
  0.64MEIP MEI Pharma Financial Report 9th of May 2024 PairCorr
  0.64CALT Calliditas Therapeutics Financial Report 21st of May 2024 PairCorr
  0.61DBVT DBV Technologies Financial Report 2nd of May 2024 PairCorr
  0.59KA Kineta Inc Report 29th of March 2024 PairCorr
The ability to find closely correlated positions to Elanco Animal could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Elanco Animal when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Elanco Animal - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Elanco Animal Health to buy it.
The correlation of Elanco Animal is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Elanco Animal moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Elanco Animal Health moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Elanco Animal can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
When determining whether Elanco Animal Health offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Elanco Animal's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Elanco Animal Health Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Elanco Animal Health Stock:
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Elanco Animal Health. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in nation.
Note that the Elanco Animal Health information on this page should be used as a complementary analysis to other Elanco Animal's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Backtesting module to avoid under-diversification and over-optimization by backtesting your portfolios.

Complementary Tools for Elanco Stock analysis

When running Elanco Animal's price analysis, check to measure Elanco Animal's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Elanco Animal is operating at the current time. Most of Elanco Animal's value examination focuses on studying past and present price action to predict the probability of Elanco Animal's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Elanco Animal's price. Additionally, you may evaluate how the addition of Elanco Animal to your portfolios can decrease your overall portfolio volatility.
Stock Screener
Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook.
Portfolio Diagnostics
Use generated alerts and portfolio events aggregator to diagnose current holdings
Crypto Correlations
Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins
CEOs Directory
Screen CEOs from public companies around the world
Commodity Channel
Use Commodity Channel Index to analyze current equity momentum
Portfolio Center
All portfolio management and optimization tools to improve performance of your portfolios
Fundamentals Comparison
Compare fundamentals across multiple equities to find investing opportunities
Is Elanco Animal's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Elanco Animal. If investors know Elanco will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Elanco Animal listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
1.097
Earnings Share
(2.50)
Revenue Per Share
8.972
Quarterly Revenue Growth
0.051
Return On Assets
0.0139
The market value of Elanco Animal Health is measured differently than its book value, which is the value of Elanco that is recorded on the company's balance sheet. Investors also form their own opinion of Elanco Animal's value that differs from its market value or its book value, called intrinsic value, which is Elanco Animal's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Elanco Animal's market value can be influenced by many factors that don't directly affect Elanco Animal's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Elanco Animal's value and its price as these two are different measures arrived at by different means. Investors typically determine if Elanco Animal is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Elanco Animal's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.